Forecast
| Buy |
1 |
| Hold |
1 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, Codiak BioSciences had revenue of €20.17M and net profit of -€36.61M
| (EUR) | 2021 | YoY |
|---|---|---|
| Revenue | 20.17M | 742.65% |
| Gross profit | 20.17M | 742.65% |
| Net profit | -36.61M | 49.86% |
| EBITDA | -24.66M | 64.34% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €0 |
52-week high/low | €3.87 - €0.0155 |
| Dividends | No |
Beta | 3.93 |
P/E ratio | -0.03 |
PEG ratio | 0.00 |
P/B ratio | 0.02 |
P/S ratio | 0.00 |
Company profile
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Name | Codiak BioSciences |
| CEO | Douglas Edward Williams |
| Headquarters | Cambridge,
ma USA |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 10/14/2020 |
| Employees | 102 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CDAK |
SIX | 32W.SW |